{
    "Trade/Device Name(s)": [
        "Dimension\u00ae EXLTM NTP Flex\u00ae Reagent Cartridge (RF623)",
        "Dimension\u00ae EXLTM LOCI\u00ae N-terminal Pro-Brain Natriuretic Peptide Flex\u00ae reagent cartridge (RF623)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K082645",
    "Predicate Device Reference 510(k) Number(s)": [
        "K080578"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "September 10, 2008",
    "Summary Letter Received Date": "September 11, 2008",
    "Submission Date": "August 15, 2008",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "B-type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "N-terminal pro-brain natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dimension\u00ae EXLTM integrated chemistry system with LOCI\u00ae Module"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay"
    ],
    "Methodologies": [
        "Sandwich immunoassay",
        "LOCI technology"
    ],
    "Submission Type(s)": [
        "Reagent Cartridge",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Dimension EXL NTP Flex Reagent Cartridge for quantitative NT-proBNP testing in serum and plasma to aid diagnosis and risk assessment of heart failure and acute coronary syndrome.",
    "Indications for Use Summary": "Quantitative measurement of NT-proBNP in human serum and plasma on the Dimension EXLTM system as an aid in the diagnosis and severity assessment of congestive heart failure, and for risk stratification of patients with acute coronary syndrome and heart failure.",
    "fda_folder": "Clinical Chemistry"
}